Early Briefing and Review: Accuray Inc., Chelsea Therapeutics Intl. Ltd, ZIOPHARM Oncology Inc., and Antares Pharma Inc. Editor Note: For more information about this release, please scroll to bottom PR Newswire LONDON, October 8, 2013 LONDON, October 8, 2013 /PRNewswire/ -- OnMonday, October 7, 2013, all three benchmark indexes of the US equity market closed lower, with the Dow Jones Industrial Average, the S&P 500, and the NASDAQ Composite falling by 0.90%, 0.85%, and 0.98%, respectively. Shares in the healthcare sector ended mostly on a lower note, tracking losses in the broader market. The major movers included Accuray Inc. (NASDAQ: ARAY), Chelsea Therapeutics International Ltd (NASDAQ: CHTP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Antares Pharma Inc. (NASDAQ: ATRS). AAAResearchReports.com has released free charting and technical research on these aforementioned companies. Register to read these reports at: http://www.aaaresearchreports.com/register/ Accuray Inc.'s stock edged higher on Monday, hitting a new 52-week high of $7.64. The company's shares fluctuated between $7.47 and $7.64 before finishing the day at $7.61, which is 0.26% higher from its previous closing price. A total of 0.66 million shares were traded which is below the daily average volume of 1.09 million. Shares in Accuray Inc. have gained 2.84% in the last three trading sessions. In the last three months the stock has surged 33.98%, outperforming the S&P 500 which has advanced 2.71% during the same period. Moreover, Accuray Inc.'s shares are currently trading above their 50-day and 200-day moving averages of $6.56 and $5.49, respectively. Sign up for free report on ARAY at: http://www.AAAResearchReports.com/ARAY100813.pdf Chelsea Therapeutics International Ltd's stock fell on Monday, tracking losses in the broader market. The company's shares hit an intraday high of $2.94 before finishing the day 1.37% lower at $2.88. A total of 0.64 million shares were traded which is below the daily average volume of 1.00 million. Shares in Chelsea Therapeutics International Ltd. have gained 15.20% in the previous three months, outperforming the S&P 500 which has gained 2.71% during the same period. Further, Chelsea Therapeutics International Ltd's stock is currently trading above its 200-day moving average of $2.04. CHTP free technical report can be accessed by signing up at: http://www.AAAResearchReports.com/CHTP100813.pdf On Monday, ZIOPHARM Oncology Inc.'s stock fell, as the broader market edged lower. The company's shares traded between $4.52 and $4.78 before finishing the day at $4.60, which is 1.71% lower than its previous day's closing price of $4.68. A total of 1.29 million shares were traded which is above the daily average volume of 0.93 million. The company's shares are currently trading 22.69% lower than the 52-week high of $5.95 and 208.72% higher than 52-week low of $1.490. Shares of the company have gained 8.75% in the previous three trading sessions. In the last three months the stock has rallied 88.52%, outperforming the S&P 500 which has advanced 2.71% during the same period. Additionally, ZIOPHARM Oncology Inc.'s shares are currently trading above their 50-day and 200-day moving averages of $3.24 and $3.13, respectively. A free report on ZIOP can be accessed by registering at: http://www.AAAResearchReports.com/ZIOP100813.pdf Antares Pharma Inc.'s stock fell on Monday, after posting gains in the previous trading session. The company's shares hit an intraday high of $4.66 before finishing the day 1.31% lower at $4.53. A total of 1.88 million shares were traded which is above the daily average volume of 1.02 million. Shares of Antares Pharma Inc. have gained 5.84% in the last three sessions. Moreover, Antares Pharma Inc.'s stock is currently trading above its 50-day and 200-day moving averages of $4.35 and $3.99, respectively. Register with AAA Research Reports and download research on ATRS for free at: http://www.AAAResearchReports.com/ATRS100813.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Peter F. Jones; +1(646)396-9126 (North America); email@example.com
Glaxo to Pay $488.7 Million Fine to End China Corruption Probe
Early Briefing and Review: Accuray Inc., Chelsea Therapeutics Intl. Ltd, ZIOPHARM Oncology Inc., and Antares Pharma Inc.
Press spacebar to pause and continue. Press esc to stop.